Terns Pharmaceuticals, Inc. EPS (Diluted)

EPS (Diluted) of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Diluted) growth rates and interactive chart. Diluted earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of diluted shares outstanding (takes into account potential dilution from options or share issuance).

Highlights and Quick Summary

  • EPS (Diluted) for the quarter ending December 31, 2021 was -0.56 (a 19.15% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Diluted) decreased by -36.36%
  • Annual EPS (Diluted) for 2021 was -2.21 (a -97.85% decrease from previous year)
  • Annual EPS (Diluted) for 2020 was -102.93 (a 3670.33% increase from previous year)
  • Annual EPS (Diluted) for 2019 was -2.73 (a 284.51% increase from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Diluted) of Terns Pharmaceuticals, Inc.

Most recent EPS (Diluted)of TERN including historical data for past 10 years.

Interactive Chart of EPS (Diluted) of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. EPS (Diluted) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.56 -0.47 -0.43 -0.88 -2.21
2020 -3.65 -0.39 -0.36 -102.93
2019 -0.39 -2.73
2018 -0.71

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.